Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by davgroon Feb 17, 2023 1:24pm
109 Views
Post# 35292468

RE:Cheap ATE Shares

RE:Cheap ATE Shares
davgro wrote: Got a partial fill of my 20000 share ATE stink bid at C.48.  Must have been a "weak hands" market sell order as the bid is back up to C.50.

Thanks for the cheap shares. :)

Sold my entire ATE position on January 17th @ C$0.64 (average) for a respectable 33% return.  I have been sitting on the sidelines ever since just watching trading activity and updatres from the company.

The recent "non-news" included in the 2023 Q3 results leads me to believe that the stock price will continue to drift lower until any substantial news is released.  I still believe in the science so I will probably acquire a new position when the stock is back in the C$0.40s.

The lack of chatter on the ATE board is telling.  I guess members realize this is now just a waiting game or they have left as they got tired of reading the Dumpster's useless posts.

GLTA
<< Previous
Bullboard Posts
Next >>